# Commission decision of 27 March 2007 on the allocation of quantities of controlled substances allowed for essential uses in the Community in 2007 under Regulation (EC) No 2037/2000 of the European Parliament and of the Council (notified under document number C(2007) 1285) (Only the Danish, Dutch, English, Estonian, French, German, Italian, Slovenian and Spanish texts are authentic) (Text with EEA relevance) (2007/211/EC), Annex II: Essential medical uses

Extent: E+W+S+N.I.

Quota of controlled substances of Group I that may be used in the production of metered dose inhalers (MDIs) for the treatment of asthma and other chronic obstructive pulmonary diseases (COPDs) are allocated to:
3 M Health Care Ltd (UK)
Bespak Europe Ltd (UK)
Boehringer Ingelheim GmbH (DE)
Chiesi Farmaceutici SpA (IT)
Inyx Pharmaceuticals Ltd (UK)
Ivax Ltd (IE)
Laboratorio Aldo Union SA (ES)
SICOR SpA (IT)
Valeas SpA Pharmaceuticals (IT)
Valvole Aerosol Research Italiana (VARI)
SpA — LINDAL Group Italia (IT)

---
Source: https://www.legislation.gov.uk/eudn/2007/211/annex/II (the official version)
Page: https://openlegislation.uk/eu-decision-2007-211/annex-II
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.